After recent studies showed an increased risk of certainly cardiovascular conditions such as stroke for patients taking rosigilitazone (Avandia), the American Heart Association issued a news release that comments on the studies and provides recommendations, including a statement that metformin should be the first choice when a glucose-lowering medication is needed. Read more here.